The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) is focused on the translation of promising basic research results into new strategies and targets for the development of new therapies for cancer and diabetes. The aim is to move these fields towards early clinical application. Top priorities include:
- Development of a safe and efficient therapy for diabetes based on human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including development of scalable differentiation protocols for functional insulin-producing beta cells.
- Establishment of human iPSC-based in vitro models for inherited forms of diabetes.
- Identification and validation of novel targets for anti-cancer therapy.
- Development of novel lead compounds for anti-cancer therapy in collaboration with industry.
The following collaborators are involved in TransStem:
- Director of Beta Cell Biology Ole Dragsbæk Madsen, Hagedorn, Novo Nordisk A/S